Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) [Phase 3]

View source ↗

Summary

A Phase 3 study to evaluate the efficacy, safety, and pharmacokinetics of a higher dose of ocrelizumab in adults with primary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING